[1]王俊霞a,贾如江b,霍浩然b,等.肝癌患者血清AHSG，NF-κB表达水平与肝动脉化疗栓塞术预后的相关性研究[J].现代检验医学杂志,2022,37(02):126-131.[doi:10.3969/j.issn.1671-7414.2022.02.026]
　WANG Jun-xiaa,JIA Ru-jiangb,HUO Hao-ranb,et al.Correlation between Serum AHSG, NF-κB Expression Levels and Prognosis of Hepatic Artery Chemoembolization in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(02):126-131.[doi:10.3969/j.issn.1671-7414.2022.02.026]
点击复制

肝癌患者血清AHSG，NF-κB表达水平与肝动脉化疗栓塞术预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
126-131
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Correlation between Serum AHSG, NF-κB Expression Levels and Prognosis of Hepatic Artery Chemoembolization in Patients with Hepatocellular Carcinoma
文章编号:
1671-7414（2022）02-126-06
作者:
王俊霞a; 贾如江b; 霍浩然b; 郭书华b
（邯郸市中心医院a. 介入科；b. 普外科，河北邯郸 056000）
Author(s):
WANG Jun-xiaa;  JIA Ru-jiangb ; HUO Hao-ranb;  GUO Shu-huab
(a. Department of Interventional; b. Department of General Surgery, Handan Central Hospital, Hebei Handan 056000, China)
关键词:
肝癌; 胎球蛋白A; 核因子-κB; 经导管动脉化疗栓塞
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.026
文献标志码:
A
摘要:
目的　分析肝癌患者血清胎球蛋白A（fetuin A ,AHSG）、核因子-κB（nuclear factor-κB ,NF-κB）水平与经导管动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）术后预后的关系。方法　选取2014 年5 月～ 2016年4 月在邯郸市中心医院普外科就诊并行TACE 的85 例肝癌患者为肝癌组，同期选取85 例医院体检结果正常者为对照组。酶联免疫吸附试验法（enzyme linked immunosorbent assay, ELISA）检测肝癌组患者行TACE 治疗前与对照组体检当日血清AHSG 和NF-κB 水平；对肝癌患者TACE 术后进行为期5 年的随访，记录患者生存情况；分析肝癌患者血清AHSG 和NF-κB 水平的相关性以及二者与临床病理特征的关系；Kaplan-Meier 法分析肝癌患者血清AHSG 和NF-κB水平与TACE 术后预后的关系；COX 回归分析影响肝癌患者TACE 术后预后不良的危险因素。结果　与对照组比较，肝癌组患者血清AHSG（14.57±3.69 ng/ml vs 5.29±1.34 ng/ml）和NF-κB（5.42±1.46 ng/ml vs 1.28±0.53 ng/ml）水平显著升高, 差异均有统计学意义（t=21.794，24.574，均P =0.000） ；肝癌患者血清AHSG 与NF-κB 水平呈正相关（r=0.495，P=0.000）；肝癌患者血清AHSG 和NF-κB 水平与AST 水平、Child-Pugh 分级、TNM 分期有关（χ2=7.051 ～17.285，均P ＜ 0.05）；AHSG 高表达组患者5 年累积生存率低于AHSG 低表达组[17.78%（8/45）vs 40.00%（16/40）]，NF-κB 高表达组5 年累积生存率低于NF-κB 低表达组[19.15%（9/47） vs 39.47%（15/38）]，差异均有统计学意义（χ2=5.161，P=0.023；χ2=4.284，P =0.038）；TNM 分期高及血清AHSG 和NF-κB 高表达是影响肝癌患者TACE 术后预后不良的危险因素（P =0.002，0.001，0.000）。结论　肝癌患者血清AHSG 和NF-κB 水平均呈高表达，二者与肝癌患者TACE 术后预后密切相关，可作为预测TACE 术后预后的潜在生物标志物。
Abstract:
Objective　To analyze the relationship between serum fetuin A (AHSG), nuclear factor-κB (NF-κB) level and prognosis after transcatheter arterial chemoembolization (TACE) in patients with liver cancer. Methods　From May 2014 to April 2016, 85 cases of liver cancer patients with TACE in the Department of General Surgery of Handan Central Hospital were selected as the liver cancer group, and 85 cases of normal physical examination results in the hospital were selected as the control group. Enzyme linked immunosorbent assay(ELISA) was used to detect the level of serum AHSG, NF-κB in patients with liver cancer before TACE treatment and on the day of physical examination in the control group. The patients with liver cancer were followed up for 5 years after TACE, record the patient’s survival, and analyzed the correlation between serum AHSG and NF- κB levels in patients with liver cancer and the relationship between them and clinicopathological features.The relationship between serum AHSG, NF-κB levels and prognosis of liver cancer patients after TACE was analyzed by Kaplan-Meier method. COX regression analysis was used to analyze the risk factors affecting the poor prognosis of patients with liver cancer after TACE. Results　Compared with the control group, the level of serum AHSG（14.57±3.69 ng/ml vs 5.29±1.34 ng/ml）, NF-κB （5.42±1.46 ng/ml vs 1.28±0.53 ng/ml）in liver cancer group was significantly higher，the differences were statistically significant (t=21.794, 24.574, all P=0.000).There was a positive correlation between the levels of serum AHSG and NF-κB in patients with liver cancer (r=0.495, P=0.000). The level of serum AHSG and NF-κB in patients with liver cancer was related to AST level, Child-Pugh grade and TNM stage (χ2=7.051~17.285, all P<0.05). The 5-year cumulative survival rate of patients with AHSG high expression group was lower than that of patients with AHSG low expression group [17.78%（8/45）vs 40.00% （16/40）], the 5-year cumulative survival rate of patients with NF-κB high expression group was lower than that of patients with NF-κB low expression group [19.15%（9/47）vs 39.47%（15/38）]，the differences were statistically significant（χ2=5.161, P=0.023；χ2=4.284, P=0.038),respectively. And high TNM stage and serum AHSG, NF-κB high expression were risk factors for poor prognosis in patients with liver cancer after TACE (P=0.002, 0.001 , 0.000). Conclusion　The levels of serum AHSG and NF-κB in patients with liver cancer were highly expressed. They were closely related to the prognosis of patients with liver cancer after TACE, and may be used as a potential biomarker to predict the prognosis after TACE.

参考文献/References:

[1] 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会，中华 医学会肝病学分会, 等. 原发性肝癌的分层筛查与 监测指南(2020 版)[J]. 中华肝胆外科杂志, 2021, 27(1): 12-29. Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Committee of Hepatology of Chinese Research Hospital Association, Society of Hepatology of Chinese Medical Association, et al. Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition) [J]. Chinese Journal of Hepatobiliary Surgery, 2021, 27(1): 12-29.
[2] HE Jingjing, YIN Xixi, WANG Ting, et al. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization [J]. Journal of Cancer Research and Therapeutics, 2021, 17(3): 777-783.
[3] 高云飞, 高凤成, 李清峰, 等. 原发性肝细胞癌患 者TACE 治疗前后血清血小板源性生长因子-BB 水 平变化及其临床意义[J]. 现代检验医学杂志, 2019, 34(6): 73-76. GAO Yunfei, GAO Fengcheng, LI Qingfeng, et al. Changes of serum platelet-derived growth factor- BB level before and after TACE treatment in patients with primary hepatocellular carcinoma and its clinical significance [J]. Journal of Modern Laboratory Medicine, 2019, 34(6): 73-76.
[4] MOHAMMADI-NOORI E, SALEHI N, MOZAFARI H, et al. Association of AHSG gene polymorphisms with serum Fetuin-A levels in individuals with cardiovascular calcification in West of Iran[J]. Molecular Biology Reports, 2020, 47(3): 1809-1820.
[5] 付双林, 李炫飞, 纪慧芹, 等. 血清胎球蛋白A、基 质金属蛋白酶14 在胃癌中表达及意义[J]. 创伤与急 危重病医学, 2020, 8(4): 250-254. FU Shuanglin, LI Xuanfei, JI Huiqin, et al. Expression and clinical significance of serum fetuin A and matrix metalloproteinase-14 in gastric cancer [J]. Trauma and Critical Care Medicine, 2020, 8(4): 250-254.
[6] SU Changming, HOU Guige, WANG Chunhua, et al. Potential multifunctional agents with anti-hepatoma and anti-inflammation properties by inhibiting NF- кB activation[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34(1): 1287-1297.
[7] ICER M A, YILDIRAN H. Effects of nutritional status on serum fetuin-A level[J]. Critical Reviews in Food Science and Nutrition, 2020, 60(11): 1938-1946.
[8] ZHENG Jun, XING Rongchun, ZHENG Weihong, et al. A comparative study on postoperative mortality prediction of SFLI scoring system and Child- Pugh classification in patients with hepatocellular carcinoma[J]. Journal of BUON , 2017, 22(3): 709-713.
[9] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011 年版)[J]. 临床肝胆病杂志, 2011, 27(11): 1141-1159. Ministry of Health of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2011) [J]. Journal of Clinical Hepatology, 2011, 27(11): 1141-1159.
[10] 中国医师协会介入医师分会. 中国肝细胞癌经动脉 化疗栓塞治疗(TACE) 临床实践指南[J]. 中华肝脏 病杂志, 2019, 27(3): 172-181. Chinese College of Interventionalists, Chinese Medical Doctor Association. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma [J]. Chinese Journal of Hepatology, 2019, 27(3): 172-181.
[11] 申鹏程, 高志强, 李丁洋, 等. 索拉非尼和预防性 TACE 对合并微血管侵犯的肝癌患者术后预防复发 的影响[J]. 中华肝脏病杂志, 2020, 28(5): 416-420. SHEN Pengcheng, GAO Zhiqiang, LI Dingyang, et al. Effect of sorafenib and prophylactic TACE for prevention of postoperative relapse in patients with liver cancer combined with microvascular invasion [J]. Chinese Journal of Hepatology, 2020, 28(5): 416-420.
[12] BOUREBABA L, MARYCZ K. Pathophysiological implication of Fetuin-A glycoprotein in the development of metabolic disorders: a concise review[J]. Journal of Clinical Medicine, 2019, 8(12): 2033.
[13] THOMAS P L, NANGAMI G, RANA T, et al. The rapid endocytic uptake of fetuin-A by adherent tumor cells is mediated by Toll-like receptor 4 (TLR4)[J]. FEBS Open Bio, 2020, 10(12): 2722-2732.
[14] SHI Feiyu, WU Hong, QU Kai, et al. Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer[J]. Clinical Proteomics, 2018, 15(6): 18.
[15] CHANG T T, HO C H. Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma. [J]. PLoS One, 2020, 15(8): e0238251.
[16] 赵杰, 余海波, 朱运海, 等. 肝癌根治术前GGT、 ALT/AST 和术后临床病理特征与预后的关系[J]. 中 华普通外科杂志, 2019, 34(4): 328-331. ZHAO Jie, YU Haibo, ZHU Yunhai, et al. Preoperative GGT, ALT/AST relates to clinicopathological features and prognosis after radical surgery for hepatocellular carcinoma [J]. Chinese Journal of General Surgery, 2019, 34(4): 328-331.
[17] HUANG Danping, YUAN Weiqu, LI Hanmin, et al. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis[J]. Experimental and Therapeutic Medicine, 2018, 16(3): 1850-1858.
[18] MIRZAEI S, ZARRABI A, HASHEMI F, et al. Regulation of nuclear factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: inhibiting or promoting carcinogenesis[J]. Cancer Letters, 2021, 509(1): 63-80.
[19] 邹庆, 官泳松, 贺庆, 等. 肝细胞癌NF-κB 表达与 CT 表现的相关性[J]. 西部医学, 2019, 31(4): 625- 628,632. ZOU Qing, GUAN Yongsong, HE Qing, et al. Hepatoocellular carcinoma: association between nuclear factor kappa B and computed tomography features [J]. Medical Journal of West China, 2019, 31(4): 625-628,632.
[20] LI Peng, GUO Hongsheng, WU Kun, et al. Decreased IL-37 expression in hepatocellular carcinoma tissues and liver cancer cell lines[J]. Oncology Letters, 2020, 19(4): 2639-2648.
[21] LI Zequn, XUAN Zefeng, CHEN Jian, et al. Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer[J]. International Journal of Oncology, 2020, 57(1): 161-170.
[22] FENG Yan, ZU Lili, ZHANG Lei. MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-κB/MMP-9/VEGF pathways[J]. Oncology Reports, 2018, 39(5): 2288-2296.
[23] 杨华, 于晓红, 高海午. 子宫内膜癌组织中COX-2, YKL-40, NF-κB 的表达及临床意义[J]. 标记免疫分 析与临床, 2020, 27(2): 242-246. YANG Hua, YU Xiaohong, GAO Haiwu. The expressions and clinical significances of COX-2, YKL- 40 and NF-κB in endometrial carcinoma [J]. Labeled Immunoassays and Clinical Medicine, 2020, 27(2): 242-246.
[24] PAN Xiongfeng, KAMINGA A C, CHEN Jihua, et al. Fetuin-A and Fetuin-B in non-alcoholic fatty liver disease: a meta-analysis and meta-regression[J]. International Journal of Environmental Research and Public Health, 2020, 17(8): 2735.
[25] JUNG T W, YOUN B S, CHOI H Y, et al. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A[J]. Biochemical Pharmacology, 2013, 86(7): 960-969.

相似文献/References:

[1]王芳胜,熊敦勇,寇辉,等.血清AFP，CEA，CA-199与TAP在肝癌诊断中的应用价值[J].现代检验医学杂志,2015,30(05):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
　WANG Fang-sheng,XIONG Dun-yong,KOU Hui,et al.Application Value of Serum AFP，CEA，CA-199 and TAP in the Diagnosis of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(02):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
[2]刘冲,唐浩,邓霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(06):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
　LIU Chong,TANG Hao,DENG Lin,et al.Research of Diagnostic Application of Serum miRNA-186 and miRNA-30c in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(02):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
[3]王 蓉,蔡高涛,钟小青,等.血清AFP-L3和GP-73联合检测对原发性肝癌诊断的Meta分析[J].现代检验医学杂志,2019,34(02):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
　WANG Rong,CAI Gao-tao,ZHONG Xiao-qing,et al.Meta Analysis of Combined Detection of Serum AFP-L3and GP-73 in Diagnosis of Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
[4]张鑫浩,张涛元,李 俏,等.基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J].现代检验医学杂志,2020,35(04):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
　ZHANG Xin-hao,ZHANG Tao-yuan,LI Qiao,et al.Screening, Identification and Bioinformatics Analysis of Key Biomarkers for Hepatocellular Carcinoma Based on GEO Chip Data[J].Journal of Modern Laboratory Medicine,2020,35(02):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
[5]王楷翔a,曹　明a,陈　晖b,等.HCV感染患者血清miR-199和miR-483水平表达及其临床价值[J].现代检验医学杂志,2021,36(05):58.[doi:10.3969/j.issn.1671-7414.2021.05.013]
　WANG Kai-xianga,CAO Minga,CHEN Huib,et al.Expression and Clinical Value of Serum miR-199 and miR-483 inPatients with HCV Infection[J].Journal of Modern Laboratory Medicine,2021,36(02):58.[doi:10.3969/j.issn.1671-7414.2021.05.013]
[6]陈　偲,王　颖a,谢生茂,等.GPRC5A对肝癌细胞增殖、凋亡和氧化应激的影响及作用机制探讨[J].现代检验医学杂志,2021,36(06):10.[doi:10.3969/j.issn.1671-7414.2021.06.003]
　CHEN Si,WANG Ying,WU Jian-jun,et al.Effects of GPRC5A on Proliferation, Apoptosis and Oxidative Stress of Hepatocellular Carcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(02):10.[doi:10.3969/j.issn.1671-7414.2021.06.003]
[7]魏　英,王小林.肝癌组织中lncRNA-PRR34-AS1的表达特性及其对肝癌细胞增殖、迁移的影响和潜在分子机制[J].现代检验医学杂志,2021,36(06):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
　WEI Ying,WANG Xiao-lin.Expression Characteristics of lncRNA-PRR34-AS1 in Liver Cancer Tissues and Its Effects on Proliferation and Migration of Liver Cancer Cells and Potential Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(02):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
[8]吴　琼,郑志存.UBE2T对肝癌细胞增殖、克隆形成及细胞周期的影响及机制研究[J].现代检验医学杂志,2022,37(02):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]
　WU Qiong,CHENG Zhi-cun.Effects of UBE2T on Proliferation, Clone Formation and Cell Cycle of Hepatocellular Carcinoma Cells and Its Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(02):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题计划项目（编号20191824）。
作者简介：王俊霞（1969-），女，本科，研究方向：肝癌介入，E-mail：wangjxx58@163.com。
通讯作者：贾如江（1974-），男，博士，主任医师，研究方向：消化系统肿瘤的基础与临床研究，E-mail：jiarujiang@163.com。
更新日期/Last Update: 1900-01-01